Translating world-class cancer research into scalable, real-world
solutions that improve prevention, early detection, and treatment.
Translating world-class cancer research into scalable, real-world solutions that improve prevention, early detection, and treatment.
CRMY Technologies Sdn Bhd (CTSB), established in 2021 (SSM Registration No. 202101031165), is the commercial arm of Cancer Research Malaysia (CRMY), created to translate research discoveries into scalable solutions.
As a wholly owned subsidiary of CRMY, CTSB manages the commercialisation of research-derived innovations, including intellectual property stewardship, licensing, and go-to-market implementation. Through this role, we enable technologies developed through CRMY’s research ecosystem to reach healthcare providers, institutional partners, and communities beyond the laboratory.
Today, CTSB supports the implementation and scaling of innovations including Genetix, MeMoSA®, and emerging therapeutic research such as CRMY’s Cancer Vaccine programme.
CRMY Technologies Sdn Bhd (CTSB), established in 2021 (SSM Registration No. 202101031165), is the commercial arm of Cancer Research Malaysia (CRMY), created to translate research discoveries into scalable solutions.
We manage patent portfolios, negotiate licensing agreements, and build joint ventures to ensure clinical research reaches the market sustainably.
As a wholly owned subsidiary of CRMY, CTSB manages the commercialisation of research-derived innovations, including intellectual property stewardship, licensing, and go-to-market implementation. Through this role, we enable technologies developed through CRMY’s research ecosystem to reach healthcare providers, institutional partners, and communities beyond the laboratory.
100% of proceeds from CTSB’s activities—including service revenues and licensing—are channelled back through donations to fuel CRMY’s ongoing foundational research.
Today, CTSB supports the implementation and scaling of innovations including Genetix, MeMoSA®, and emerging therapeutic research such as CRMY’s Cancer Vaccine programme.
From foundational science to commercial implementation, working
together to defeat cancer.
From foundational science to commercial implementation, working together to defeat cancer.
Private charitable research entity focusing on foundational cancer research, validation studies, and scientific discovery.
Fully owned commercial arm scaling research via IP management, go-to-market strategies, and commercial laboratory services.
A multidisciplinary group of clinicians,
technologists, and operators united by one
mission — translating cancer research into
real-world impact.
A multidisciplinary group of clinicians, technologists, and operators united by one mission — translating cancer research into real-world impact.
Our platforms are continuously validated by a distinguished network
of clinical specialists, dental reviewers, and institutional partners —
ensuring every standard of care is met and exceeded.
Our platforms are continuously validated by a distinguished network of clinical specialists, dental reviewers, and institutional partners — ensuring every standard of care is met and exceeded.
